Archives

img-01

日本促进增加仿制药的接受率

日本厚生省(MHLW)已经宣布计划,鼓励保险公司进一步促进仿制药。日本最近的调查发现,费用高的药品的仿制药处方率很低。 日本医生对他们可以处方的仿制药也越来越挑剔。这在很大程度上是因为担忧药品的质量以及仿制药的成分和原研药的一致程度。 日本厚生省(MHLW)还计划增加非处分药物(OTC)的数量。目前,日本仅10%的药物可以没有处方购买。相比较,美国有20%的药物是OTC药。 将药物重新分类为OTC将使得日本政府每年节约医保费用、医院护理费用及其他医疗成本。 Read More

img-01

Japan Expands Orphan Drug Designation Criterion

On April 1, 2015, Japan’s Ministry of Health, Labor and Welfare (MHLW) notified stakeholders of an updated criterion for orphan drug designation. This change will likely apply to the orphan medical device designation system as well. Drugs that treat “designated intractable diseases”... Read More

img-01

Japan Promotes Increases in Drug Accessibility

The Japanese Ministry of Health, Labor and Welfare (MHLW) has announced plans to encourage insurance companies to further promote generic drugs. Recent surveys in Japan have found a low rate of generic drug prescriptions for high cost medicines. Japanese doctors are increasingly... Read More

img-01

Japan: Medical Device and Pharmaceutical Reviews

The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) recently announced that it would aim for increased speed to market for innovative medical devices and pharmaceuticals. The PMDA plans to complete 70% of device and pharmaceutical reviews within 12 months in 2015– compared... Read More

img-01

Asia Medical Device Markets Overview Presentation

This presentation provides an overview of the Asian medical device markets and covers important regulatory issues for specific Asian countries, including China, Japan, India, Thailand, and Vietnam. To view these presentation slides, please click on Asia Medical Device Markets Overview Presentation Table of... Read More